• MJHLS Brand Logo

© 2020 MJH Life Sciences™ and Rheumatology Network. All rights reserved.

7 New Drugs for Rheumatology in 2018

July 30, 2018
Rheumatology Network Staff

Here’s a brief look at medications for rheumatologic disorders that were approved or granted a new indication in 2018.

Here’s a brief overview of medications for rheumatologic disorders that were approved or granted a new indication in 2018.

Scroll through the slides for details about new treatments for rheumatoid arthritis, osteoarthritis, ulcerative colitis, plaque psoriasis, osteoporosis, and juvenile arthritis.

RELATED CONTENT

May 2019:  FDA Rheumatology Drug Approvals: Pediatric lupus, spondyloarthritis and more

April 2019:  Etanercept Biosimilar Approved for RA and Other Conditions

April 2019:  New Drug Approvals and more Drug News from Rheumatology Network

Rheumatoid Arthritis: Olumiant (baricitinib) Tablets, a 2-mg, once-daily oral Janus kinase inhibitor for the treatment of adults with moderate to severe active RA who have had an inadequate response to one or more tumor necrosis factor inhibitor therapies. (Approved 5/31/2018, Eli Lilly and Company)

For more information, please see FDA Gives Nod to Baricitinib 2-mg Tablets for Moderate to Severe RA in Adults.

Hypertension and Osteoarthritis: Consensi (amlodipine and celecoxib), a calcium channel blocker and nonsteroidal anti-inflammatory drug combination for the treatment of both hypertension and pain associated with osteoarthritis. (Approved 5/31/2018, Kitov Pharma Ltd.)

Ulcerative Colitis: Xeljanz (tofacitinib), a Janus kinase inhibitor, received an indication for the treatment of adult patients with moderately to severely active ulcerative colitis. (Approved 5/30/2018, Pfizer)

Plaque Psoriasis: Cimzia (certolizumab pegol) received an indication for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. (Approved 5/25/2018, UCB)

For more information, please see Certolizumab Gets FDA Nod for Moderate to Severe Plaque Psoriasis in Adults.

Glucocorticoid-Induced Osteoporosis: Prolia (denosumab), a human monoclonal antibody approved for the treatment of glucocorticoid-induced osteoporosis in men and women at high risk for fracture. (Approved 5/21/2018, Amgen)

For more information, please see FDA Gives Nod to Denosumab for Glucocorticoid-Induced Osteoporosis.

Juvenile Idiopathic Arthritis: Actemra (tocilizumab) subcutaneous formulation approved for the treatment of active polyarticular juvenile idiopathic arthritis (PJIA) in patients 2 years of age and older. (Approved 5/14/2018, Genentech)

Plaque Psoriasis: Ilumya (tildrakizumab-asmn), a novel interleukin-23 inhibitor for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. (Approved 3/21/2018, Sun Pharmaceuticals)

For more information, please see Tildrakizumab Gets FDA Nod for Moderate to Severe Plaque Psoriasis.

PreviousNext